Coherus Oncology (CHRS)

• Market cap: $219M
• 1 day: -2.07%
• 5 days: -8.97%
• 1 month: -18.86%
• 3 months: -26.42%
• 6 months: 10.94%
• Year to date: 3.65%
• 1 year: 66.2%
• 5 years: -89.52%
• 10 years: -92.13%
• Sector: Healthcare
• Industry: Biotechnology

About: Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Employees: 145